Glaucoma, one of the world's leading causes of irreversible blindness, is expected to affect an estimated 120 million by 2040, globally. Treatment options for management of Referable Glaucoma (a stage of the disease where immediate treatment can help manage the disease better) exist, but a simple test to screen for this has been elusive. Today, the only way to detect those with Referable Glaucoma is a series of complex investigations often requiring multiple devices handled by Glaucoma Specialists. Remidio Innovative Solutions, together with Aravind Eye Hospital (AEH), Pondicherry, and Narayana Nethralaya (NN), Bangalore, announced the results of a landmark clinical trial that can help revolutionize the detection of Referable Glaucoma. The integrated solution provides an instant report in contexts where there are no specialists.

Many causes of vision loss that can be prevented or treated are cumulatively termed as avoidable Blindness, including conditions such as cataracts, refractive errors, xerophthalmia, trachoma, glaucoma, and diabetic retinopathy. Due to its image recognition capabilities, AI has been growing in popularity where image analysis is essential to disease diagnosis and treatment. AI-based systems are trained with many pictures of the eye, following which the algorithms learn the difference between normal images and abnormal images. And early diagnosis and treatment can prevent or minimize vision loss or impairment. Telangana government was concerned about the high number of blindness and vision impairment cases that occurred in children due to a lack of trained and skilled ophthalmologists.

Artificial intelligence is perhaps one of, if not, the most disruptive technologies of this era. Although it has been practised for over 60 years, AI has really emerged as a practical part of operations across industries in the last decade or so. Healthcare is one such sector where its impact promises to be far-reaching. Of the numerous benefits AI has to offer, enhanced patient safety and greater accessibility are the most obvious ones. A report titled'Artificial Intelligence (AI): Healthcare's new nervous system' by Accenture estimates that health AI market in the US will be worth USD 6.6 billion by 2021, with a staggering CAGR of 40 percent.

Google and Verily, Alphabet's life sciences and healthcare arm, have created a machine learning algorithm to help screen for diabetic retinopathy and diabetic macular edema, according to a Google blog post. The development of the algorithm has been a three-year project, which also involved the organizations conducting a global clinical research program focused on India. Verily has received a CE mark for the algorithm. Now, they've revealed the first real-world clinical use of the algorithm is happening at Aravind Eye Hospital in Madurai, India. At the hospital, the process works like this: Technicians use a fundus camera to take one image of each of the patient's eyes.

Parent company Alphabet's Google and Verily are using machine knowledge to help screen diabetic retinopathy (DR) and diabetic macular edema (DME). The two eye conditions are one of the major causes of blindness and if everything works well, it may facilitate automated screening. Which means that it will be able to detect disease sooner and provide more people with access to screenings. A part of Google's parent company Alphabet called Verily is working with Google to conduct clinical research around the world, especially in India, where studies showed the algorithm was as good at assessing images for disease as general ophthalmologists and retinal specialists, according to a blog post from the companies. Artificial Intelligence Can Detect Heart Problems in the Future, Says Study by Mayo Clinic. The "First real-world clinical use of the algorithm" has been initiated at Aravind Eye Hospital in Madurai as a result of the research.

Six titans of industry stood onstage at MIT's Kresge Auditorium yesterday, assembled to speak on a panel about artificial intelligence (AI), including David H. Koch Institute professor Robert Langer; Helen Greiner, cofounder of iRobot, the Bedford-based company perhaps best known for its line of autonomous vacuum cleaners; Xiao'ou Tang, founder of computer vision startup SenseTime, which last year raised $1.2 billion in venture capital at a valuation of more than $4.5 billion; and Eric Schmidt, former executive chairman of Google. The discussion capped off a three-day celebration of MIT's new Stephen A. Schwarzman College of Computing, which will offer its first classes in physics, economics, biology, economics, machine learning, and related disciplines this fall. The panelists shared thoughts on a range of topics, but one they repeatedly touched on was entrepreneurship. Entrepreneurs, Schmidt argued in his opening remarks, drive the economy -- they're spigots for ideas that form the basis of industries. "[Founders are] people who are filled with a vision -- something they care about -- and they personalize it, they believe in it, and they convince others to follow them," he said. But, he said, they're in "need [of] more juice."

Dr Ramasamy Kim is looking at the inside of an eyeball. There is nothing particularly surprising about that: he is head of retina services at an eye hospital in southern India. The image on his computer screen shows the first blush of a condition linked to diabetes that affects millions of Indians – and can lead to blindness. The diagnosis was made not by him, or any other doctor, but by an algorithm. Over the past five years, Kim and his team at the Aravind eye hospital in Madurai have examined about 15,000 images from across the country showing the interior surface of the eyeball, known as the fundus.

In a world with limited doctors, emerging diseases and superbugs, and sharply rising costs, how can we successfully tackle health care problems at scale? This is just one of the critical challenges India's explosive startup community hopes to solve by implementing AI to serve the needs of the country's 1,324 billion citizens. The result of this effort will have huge implications for the U.S. and other health care ecosystems around the globe. To understand how dire the situation is, it's worth considering India's health paradox. The country's deep demographic dividend -- which occurs when the majority of a country's population consists of working-age individuals -- is driving rapid and unprecedented growth, but it is also a ticking time bomb.

One of the principal causes of blindness is Diabetic Retinopathy (DR), a medical condition in which damage occurs to the retina due to diabetes. According to the United States National Library of Diabetes, more than 40 percent of Americans diagnosed with diabetes have some stage of Diabetic Retinopathy. The International Diabetes Federation estimates that are 415 million diabetic patients worldwide have the risk of DR. The severity is identified by the presence of lesions that indicate bleeding and fluid leakage in the eye. Only experienced doctors and specialists can scan and interpret these pictures.

One of the principal causes of blindness is Diabetic Retinopathy (DR), a medical condition in which damage occurs to the retina due to diabetes. According to the United States National Library of Diabetes, more than 40 percent of Americans diagnosed with diabetes have some stage of Diabetic Retinopathy. The International Diabetes Federation estimates that are 415 million diabetic patients worldwide have the risk of DR. The severity is identified by the presence of lesions that indicate bleeding and fluid leakage in the eye. Only experienced doctors and specialists can scan and interpret these pictures.